Amlodipine/benazepril detailed information
Jump to navigation
Jump to search
| File:Amlodipine.svg | |
| File:Benazepril.svg | |
| Combination of | |
|---|---|
| Amlodipine | Calcium channel blocker |
| Benazepril | ACE inhibitor |
| [[{{{component3}}}]] | ? Class |
| [[{{{component4}}}]] | ? Class |
| [[{{{component5}}}]] | ? Class |
| [[{{{component6}}}]] | ? Class |
| Gene therapy | |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| Physiological data | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Identifiers | |
| PubChem Template:Abbreviation | |
| Chemical and physical data | |
Amlodipine/benazepril, marketed in the U.S. as Lotrel by Novartis and manufactured as a generic drug by Teva, is an antihypertensive medication which combines a calcium channel blocker (amlodipine besylate) with an angiotensin converting enzyme inhibitor (benazepril). This combination agent, and other analogs, is prescribed when either agent alone is not sufficient to bring a person's blood pressure down to target range. As a combination agent, Lotrel shares the adverse reaction profile of both of its individual parts.
External links
Categories:
- Articles with short description
- Pages with broken file links
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Calcium channel blockers
- ACE inhibitors